Premium
The role of monoamine oxidase in the metabolism of exogenous noradrenaline by the human saphenous vein *
Author(s) -
Branco D.,
Caramona M.,
Araújo D.,
Osswald W.
Publication year - 1992
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1992.tb00105.x
Subject(s) - deamination , oxidative deamination , monoamine oxidase , norepinephrine , biochemistry , chemistry , metabolism , vein , monoamine oxidase a , endocrinology , medicine , enzyme , biology , dopamine
Summary— Human saphenous vein segments were obtained from patients subjected to coronary bypass surgery. As determined by HPLC‐ED, the veins had a relatively low content of noradrenaline and high content of the deaminated metabolites, dihydroxyphenylglycol (DOPEG) and dihydroxymandelic acid (DOMA). In vein segments which had been incubated with 3 H‐noradrenaline (0.1 μmol/l), the oxidative deamination pathway predominated over the 0‐methylating one. Deamination occurred both at the neuronal and extraneuronal level; DOPEG appearing to be a good index of intraneuronal deamination, whereas DOMA and O‐methylated and deaminated metabolites were mainly formed extraneuronally. Both MAO type A and MAO type B selective inhibitors reduced the deamination of noradrenaline; deamination was also found to be partially sensitive to semicarbazide. Inhibition of neuronal uptake or of deamination increased O‐methylation. The human saphenous vein thus metabolizes exogenous noradrenaline following a pattern which substantially differs from that shown to occur in various blood vessels from other animal species.